[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613175":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":25,"responsibleParty":35,"collaborators":25,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":41,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":25,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":62,"whyStopped":25,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":25},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexmedetomidine + Bupivacaine","EXPERIMENTAL","Participants will receive an ultrasound-guided external oblique intercostal plane block using 20 mL of 0.25% bupivacaine combined with dexmedetomidine (0.5 µg\u002Fkg) administered as a single-shot injection.",[13],"Drug: Dexmedetomidine",{"label":15,"type":16,"description":17,"interventionNames":18},"Bupivicaine","ACTIVE_COMPARATOR","Participants will receive an ultrasound-guided external oblique intercostal plane block using 20 mL of 0.25% bupivacaine administered as a single-shot injection without any adjuvant.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Dexmedetomidine","Dexmedetomidine as Adjuvant toBupivacaine in Ultrasound Guided ExternalOblique Intercostal Plane Block",[15,9],null,[27,32],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"Mohamed i Shaker","CONTACT","01012248619","aboiprahem1997@gmail.com",{"name":33,"role":29,"phone":25,"phoneExt":25,"email":34},"Moaaz M Tohamy","moaaz@aun.edu.eg",{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Mohamed Ibrahem Shaker","Anesthesia Resident","100613175","dexmedetomidine-as-an-adjuvant-to-bupivacaine-for-ultrasound-guided-external-oblique-intercostal-block-100613175",false,"NCT07263165","Dexmedetomidine as an Adjuvant to Bupivacaine for Ultrasound-Guided External Oblique Intercostal Block","Effect of Adding Dexmedetomidine as Adjuvant to Bupivacaine in Ultrasound Guided External Oblique Intercostal Plane Block in Upper Abdominal Cancer Surgery. A Prospective Randomized Clinical Trial","Dexmedetomidin","Inclusion Criteria:\n\n* Patients aged 18-70 years scheduled for elective upper abdominal cancer surgery (e.g., gastrectomy, hepatectomy, pancreatectomy).\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Body mass index (BMI) between 18-35 kg\u002Fm².\n\nExclusion Criteria:\n\n* Patient refusal.\n* Allergy to local anesthetics or dexmedetomidine.\n* Coagulopathy (INR \\>1.5, platelet count \\\u003C100,000\u002Fmm³).\n* Infection at the injection site.\n* Severe cardiopulmonary, renal, or hepatic dysfunction.\n* Chronic opioid use (\\>30 mg morphine equivalents daily for \\>3 months).\n* Pregnancy or lactation.","ALL","18 Years","70 Years",{"count":51,"type":52},54,"ESTIMATED","INTERVENTIONAL",[55],"NA","Effect of Adding Dexmedetomidine as Adjuvant toBupivacaine in Ultrasound Guided ExternalOblique Intercostal Plane Block in UpperAbdominal Cancer Surgery.",[58],"Opioid Consumption, Postoperative",[60,61],"dexmedetomidine","external oblique intercostal block","NOT_YET_RECRUITING","2025-11-23",{"date":65,"type":66},"2025-12-04","ACTUAL",{"date":68,"type":52},"2025-12-15",{"date":70,"type":52},"2027-12-15",{"name":5,"class":6}]